SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 25th, 2016 • Sparkle Byte LTD • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is made as of September 20, 2015, between CASI Pharmaceuticals, Inc., a Delaware corporation (the “Company”), He Xie Ai Qi Investment Management (Beijing) Co., Ltd. (和谐爱奇投资管理（北京）有限公司), a company formed under the laws of the People’s Republic of China (“HXAQ”) and any Person that delivers any portion of the Subscription Amount pursuant to Section 2.02(b) of this Agreement (such Persons, together with HXAQ, jointly and severally, and including their successors and assigns, the “Purchaser”).
JOINT FILING AGREEMENT January 25, 2016Joint Filing Agreement • January 25th, 2016 • Sparkle Byte LTD • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree (i) to the joint filing, on behalf of each of them, of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.01 per share of CASI Pharmaceuticals, Inc., a Delaware corporation; and (ii) that this agreement be included as Exhibit 99.1 to such joint filing. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.
